Introduction
Biochemical monitoring during antihypertensive drug therapy can identify changes related to potential adverse drug reactions (ADRs) before they have caused serious or permanent effects, and so avert harm. Specific guidance on monitoring for ADRs for healthcare professionals is available from several sources, such as publications from government organizations, professional societies, and independent researchers or research groups.
Ideally, monitoring instructions should provide details on several factors: the purpose of monitoring, the appropriate frequency of monitoring and how to act on the results of a monitoring test. 1 However, published guidelines can provide divergent or incomplete recommendations on monitoring for ADRs. We have previously shown that monitoring, as recommended by published guidelines, is not commonly undertaken in primary care. 2 We hypothesized that that might be in part because the available guidelines are incomplete and inconsistent. 3 We therefore set out to determine, by systematic review, the nature and extent of recommendations in published guidelines on biochemical monitoring for adverse reactions to drugs used in the treatment of hypertension, and to synthesize practicable recommendations based on the findings.
Methods
We searched for published guidelines that described methods of monitoring for adverse reactions in patients being treated for hypertension. We defined monitoring as a description of measurement of serum creatinine, potassium or sodium concentrations during treatment with angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II receptor antagonists or diuretics.
We searched Medline using the OVID interface from January 2001 to October 2011 using the MeSH term 'Hypertension/drug therapy', limiting the results to the publication type 'practice guideline'. We also searched the National Guideline Clearinghouse (NGC) database (www.guideline.gov) and the TRIP database (www.tripdatabase.com) using the search term 'hypertension'.
Guidelines relating specifically to the treatment of hypertension in pregnant women, children or teenagers were excluded, as were guidelines relating specifically to the use of antihypertensive drugs in the treatment of heart failure and chronic kidney disease, for which monitoring is often more relevant to the condition rather than the treatment. We did not identify any guideline dealing specifically with hypertension in liver disease. The full search strategy is given in Supplementary Appendix A; please see http://jrs. rsmjournals.com/lookup/suppl/doi:10.1258/ jrsm.2012.120137/-/DC1.
Data synthesis
We examined all the guidelines selected for inclusion, and determined the recommendations that were made and where there was disagreement between them, also noting the absence of recommendations. We also determined what evidence had been cited in support of the recommendations. We then synthesized a set of guidelines based on the recommendations for which there was general or majority agreement and resolved inconsistencies by discussion. We predicated our discussions on the principle that monitoring should be of the lowest intensity consistent with basic principles of safe practice.
Results
We screened 88 abstracts from Medline, 105 guidelines from the TRIP database and 82 guidelines from the NGC database ( Figure 1 ). We identified 19 sets of published guidelines in which details on biochemical monitoring were provided (Supplementary Appendices B and C; http://jrs. rsmjournals.com/lookup/suppl/doi:10.1258/ jrsm.2012.120137/-/DC1). 4 -22 Three published guidelines identified by the search have subsequently been withdrawn or superseded and were therefore excluded (Supplementary Appendix D; http://jrs.rsmjournals.com/lookup/suppl/doi: 10.1258/jrsm.2012.120137/-/DC1). 23 -25 Tables 1-3 summarize the published guidelines, giving information on monitoring serum creatinine concentration in patients taking ACE inhibitors or angiotensin-II receptor antagonists, and electrolytes in patients taking ACE inhibitors, angiotensin-II receptor antagonists or diuretics.
Monitoring recommendations from the guidelines can be divided into those that are required pretreatment, following treatment initiation and during continued therapy (see Table 1 ). For all three drug classes, the guidelines were more likely to recommend baseline monitoring of the selected parameters before treatment, than they were for early and continued therapy.
There was a difference in the recommendations made for continued ACE inhibitor or angiotensin-II receptor antagonist therapy, with more emphasis placed on the need to monitor the potassium concentration (n = 8/17) than the creatinine concentration (n = 3/18).
Guidelines differed in their advice on actions to take when electrolyte concentrations changed.
For ACE inhibitors and angiotensin-II receptor antagonists, five guidelines recommended a course of action should the potassium Finally, only three guidelines advised monitoring following a change in dose of ACE inhibitors or angiotensin-II receptor antagonists, and none for diuretic therapy.
Thirteen guidelines made no reference to any primary research supporting the monitoring guidance. Five referenced previously published guidelines, reviews or guidelines reporting the epidemiology of the ADRs during antihypertensive drug treatment. One guideline made no explicit reference to primary evidence, but instead graded the evidence as Grade D (i.e. based on expert opinion alone). Table 4 shows the practical recommendations that we have distilled from a synthesis of the findings of this review. For each drug class, we have suggested baseline monitoring before treatment, followed by monitoring during early treatment, at incremental dose changes, and during continued therapy. These recommendations are designed to provide efficient monitoring, by reducing the number of tests to a minimum and aligning monitoring schedules, allowing creatinine, potassium and sodium concentrations to be measured at the same times in all cases. In addition, we have provided advice to assist the practitioner should a change in measurement occur.
Discussion
We have identified a corpus of published guidelines on the treatment of patients with ACE inhibitors, angiotensin-II receptor antagonists and diuretics for hypertension, which differ in their advice on monitoring for ADRs, both in the extent of advice and in the details. Many give only rudimentary guidance or none at all. Where present, details differed substantially between guidelines. Some described monitoring as a 'routine investigation' or suggested that laboratory tests should be 'measured every 6-12 months'. Such poorly specified recommendations are challenging for clinicians to apply in clinical practice.
A few guidelines gave far more detailed recommendations, specifying biochemical testing before the start of therapy, the frequency and nature of follow-up monitoring, and actions to be taken should the laboratory results be outside a stated range. 9 Where details were given, they were inconsistent between guidelines. For example, of the 12 guidelines suggesting monitoring of serum potassium concentration during maintenance therapy with ACE inhibitors or angiotensin-II receptor antagonists, three described them as routine, one recommended monitoring every 3 -6 months, two every 6-12 months and five annually. This lack of consensus is bound to result in confusion.
Finally, we found that guidelines rarely referenced primary evidence supporting the monitoring recommendations, as has been shown previously. 26 Sica 27 described guidelines for monitoring serum potassium concentrations in patients treated with antihypertensive drugs as 'at best makeshift and often drawn from the know-how of the treating physician'.
The aim of this systematic review was to determine the nature and extent of recommendations in published guidelines on biochemical monitoring for adverse reactions to drugs used in the treatment of hypertension, and to synthesize practicable recommendations based on the findings. Our monitoring recommendations are designed to minimize the risk of patient harm, optimize therapy and provide physicians with actionable changes should adverse effects occur. We recommend baseline monitoring of parameters for each drug class, so that any fluctuations in concentrations can be more easily attributable to the treatment. Baseline testing also ensures that the patient starts treatment at an appropriate dose, and that the drug is not already contraindicated. We then recommend repeated monitoring within two weeks of starting treatment, so that any adverse reactions can be identified early, and any incremental dose increases can be made safely. In each case, if measurements have changed from baseline tests, actionable changes in the monitoring or dosing of treatment ensure an alternative management plan for the patient. Clinicians often face the difficulty of divergent or incomplete recommendations in clinical guidelines. Here we have shown how systematic review and synthesis can yield more complete guidance in one specific case. This process may be more generally applicable.
Limitations of this review
We selected guidelines published in English or French, but we nevertheless believe that the results are widely applicable. Although formal recommendations on how to assess guidelines have been published, 28 we did not evaluate the quality of the guidelines, because most of them were not written with the specific goal of describing monitoring in patients treated with antihypertensive drugs. Instead, most were written on the treatment of hypertension, and monitoring for ADRs was incidentally included. We have based our recommendations on the published guidelines, but these are not themselves based on clear evidence.
Conclusions
There is a need for detailed information on what, when and how to monitor in the management of hypertension and the adverse effects of antihypertensive drugs; specifically, we need more evidence on the ideal frequencies of monitoring, the Journal of the Royal Society of Medicine circumstances in which extra monitoring is indicated and guidance on the thresholds at which actions are required. However, in the absence of any evidence of the outcomes of different monitoring schemes, there is no underlying knowledge of the relevant detail, which relies on consensus and is of unproven value. Only good outcome data can resolve this. Meanwhile, without better evidence, the recommendations distilled from this systematic review should help practitioners when they monitor drug therapy in hypertension. 
